View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 17, 2021updated 11 Jul 2022 2:17pm

Tevogen Bio doses subjects in Covid-19 immunotherapy trial

The trial will evaluate the safety, efficacy and optimal dose of TVGN-489 in adult patients with Covid-19. 

Tevogen Bio has concluded dosing of the first cohort of subjects in the proof-of-concept clinical trial of its experimental immunotherapy, TVGN-489, to treat Covid-19 in the high-risk population.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

TVGN-489 has SARS-CoV-2 particular cytotoxic CD8+ T lymphocytes (CTLs), which can potentially identify targets spread across the complete viral genome.

Tevogen Bio noted that such targeted CTLs can potentially detect and destroy virally infected cells.

The single centre, open-label trial will assess the safety, efficacy and optimal dose of TVGN-489 in adults aged 18 years and above with Covid-19.

It is recruiting subjects who are at increased risk of severe disease advancement either because of their advanced age or any underlying health issues.

The outcomes from subjects who receive TVGN-489 in Arm A will be compared with people receiving the standard of care in Arm B of the trial.

So far, no dose-limiting toxicities or treatment-linked side effects were reported in any of the three subjects who received a single low-dose infusion of the drug candidate.

These participants were observed in the hospital for four days before being discharged and daily for another ten days in the at-home setting.

The second group of subjects in the study will be given a higher dose of the experimental immunotherapy and monitored in the same manner.

The trial will have up to four dosing levels of TVGN-489.

Tevogen CEO Ryan Saadi said: “Preclinical data of TVGN-489 exhibited strong antiviral activity against SARS-CoV-2, and we are hopeful that the proof of concept study will demonstrate the viability of our investigational T cell therapy to address the significant unmet need in treating Covid-19 patients who are at-risk for more severe outcomes.”

In May this year, the company reported data from a preclinical study where TVGN-489 showed robust antiviral activity against SARS-CoV-2.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena